cz
en

DiAMonD – DIscovering Active MicroOrgaNisms implicated in adverse Drug effects

Projects

Objective of the project:

The microbiome plays relevant functions on human health and disease, including roles in the efficacy and security of drug treatments. Capecitabine is a pro-drug of 5-fluorouracil, which is an active metabolite that targets tumor cells. This treatment is used for diverse cancers, including colon tumors, and is commonly associated with diverse adverse reactions such as the hand-foot syndrome (HFS), a skin deterioration for which there has not been discovered its causal mechanism. Preliminary data suggest that some skin microbes interact with 5-flourouracil.

In this project, the researcher will focus on studying the dynamics and features of the skin microbiome of patients treated with capecitabine. This project will provide understanding related with the roles of the skin microbiome in the appearance or protection against a skin adverse drug reaction. This knowledge may be used for the advance of a precise and personalized medicine in which the individual microbiome can be considered.

AcronymDiAMonD
Number and ID code of the projectN° 101090267, HORIZON-WIDERA-2022-TALENTS-02
Type of the projectHORIZON-TMA-MSCA-PF-EF
CoordinatorInstitute of Microbiology of the CAS, v.v.i.
IMIC Principal Researcherdr. Zaki Saati Santamaría
Start of the project7/2024
End of the project6/2026
Total number of particip. countries1
Of which from EU1
Number of partners0
Total funding for the project166 278,72 EUR
Funding for IMIC166 278,72 EUR
ProviderProgram EU Horizon Europe HORIZON-WIDERA-2022-TALENTS-02gion